Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.49 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 3/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12776101 | 0.87 | RIPK1 (0.61) | RIPK1SSTR4KDM1AMAOBALOX5AP | |
| SCHEMBL16629598 | 0.85 | SSTR4 (0.47) | RIPK1SSTR4MCHR1KDM1AMAOB | |
| SCHEMBL22391511 | 0.81 | RIPK1 (0.55) | RIPK1SSTR4MCHR1KDM1AMAOB | |
| SCHEMBL22391509 | 0.81 | RIPK1 (0.55) | RIPK1SSTR4MCHR1KDM1A | |
| SCHEMBL12776096 | 0.78 | SLC13A5 (0.48) | RIPK1SSTR4MEN1KMT2ASLC13A5 | |
| SCHEMBL19149245 | 0.77 | NFE2L2 (0.41) | SSTR4MCHR1KDM1AMAOBNFE2L2 | |
| SCHEMBL18014773 | 0.76 | RIPK1 (0.49) | RIPK1SSTR4ALOX5APFEN1 | |
| SCHEMBL12776098 | 0.76 | SLC13A5 (0.47) | RIPK1KDM1AMAOBNFE2L2MEN1 | |
| SCHEMBL23344679 | 0.74 | SCN9A (0.41) | RIPK1SSTR4 | |
| SCHEMBL19147813 | 0.73 | SSTR4 (0.43) | SSTR4MCHR1NFE2L2OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | BACE1, BACE2, PSEN2 | RIPK1 2370/4885SSTR4 4138/4885MCHR1 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.